Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

NCT02211690 is registered in ClinicalTrials.gov with Andrew Carr as lead sponsor.

NCT NCT02211690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02211690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis
Lead sponsor
Andrew Carr
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2014
Completion date
February 29, 2016
Enrollment
100 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus